DDInter1925 DDInter1747
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Vemurafenib {u} (Compound) resembles {v} (Compound) Etoricoxib
Vemurafenib {u} (Compound) treats {v} (Disease) skin cancer
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
Vemurafenib {u} (Compound) upregulates {v} (Gene) DHRS12
Vemurafenib {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Vemurafenib {u} (Compound) downregulates {v} (Gene) CLPP
Vemurafenib {u} (Compound) causes {v} (Side Effect) Eosinophilia
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Vemurafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Vemurafenib (Compound) resembles Etoricoxib (Compound)
Vemurafenib (Compound) treats skin cancer (Disease)
Vemurafenib (Compound) binds CYP3A4 (Gene)
Vemurafenib (Compound) upregulates DHRS12 (Gene)
Vemurafenib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Vemurafenib (Compound) downregulates CLPP (Gene)
Vemurafenib (Compound) causes Eosinophilia (Side Effect)
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan